BeOne Medicines (ONC) Current Assets (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Current Assets of $6.6 billion for Q1 2026, up 69.42% year-over-year from $3.9 billion in Q1 2025, and up 5.9% quarter-over-quarter from $6.2 billion in Q4 2025.
BeOne Medicines (ONC) Current Assets (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Current Assets for 12 consecutive years, with $6.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 69.42% year-over-year to $6.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 69.42% YoY), while the FY2025 annual figure was $6.2 billion, up 56.17% from the prior year.
- Current Assets grew to $6.6 billion in Q1 2026 per ONC's latest filing, from $6.2 billion in the prior quarter.
- Across five years, Current Assets topped out at $6.9 billion in Q1 2022 and bottomed at $3.1 billion in Q4 2022.
- Historically, Current Assets has averaged $4.8 billion across 5 years, with a median of $4.3 billion in 2025.
- Annual changes were most pronounced in 2022 — Current Assets tumbled 59.33% — and 2026, when it jumped 69.42%.
- BeOne Medicines' Current Assets stood at $3.1 billion in 2022, then jumped by 35.74% to $4.2 billion in 2023, then dropped by 5.04% to $4.0 billion in 2024, then surged by 56.17% to $6.2 billion in 2025, then grew by 5.9% to $6.6 billion in 2026.
- Business Quant data shows ONC's Current Assets at $6.6 billion in Q1 2026, $6.2 billion in Q4 2025, and $5.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.22 Bn |
| Mar 31, 2026 | 6.60 Bn |
| Dec 31, 2025 | 6.23 Bn |
| Sep 30, 2025 | 5.66 Bn |
| Jun 30, 2025 | 4.31 Bn |
| Mar 31, 2025 | 3.90 Bn |
| Dec 31, 2024 | 3.99 Bn |
| Sep 30, 2024 | 3.91 Bn |
| Jun 30, 2024 | 3.84 Bn |
| Mar 31, 2024 | 3.91 Bn |
| Dec 31, 2023 | 4.20 Bn |
| Sep 30, 2023 | 4.05 Bn |
| Jun 30, 2023 | 4.40 Bn |
| Mar 31, 2023 | 4.70 Bn |
| Dec 31, 2022 | 3.10 Bn |
| Sep 30, 2022 | 5.75 Bn |
| Jun 30, 2022 | 6.35 Bn |
| Mar 31, 2022 | 6.95 Bn |
| Dec 31, 2021 | 7.61 Bn |
| Sep 30, 2021 | 4.43 Bn |